← back to search

John A. Lawson

Universities UK · AU
Area of research
Biochemistry · Pharmacology
Research interest
Research interests include Inflammatory mediators and NSAID effects, Epilepsy research and treatment, Eicosanoids and Hypertension Pharmacology, and Antioxidant Activity and Oxidative Stress.
h-index
82
citations
23,467
works
420
NIH funding
primary concept
email

Recent publications

Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE) (P14-1.004)
Neurology 2023cited by 2position: middledoi
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
Epilepsia 2022cited by 33position: lastdoi
Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies
Neurology 2021cited by 94position: middledoi
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia
Haematologica 2021cited by 55position: middledoi
Adjunctive everolimus therapy for tuberous sclerosis complex‐associated refractory seizures: Results from the postextension phase of EXIST‐3
Epilepsia 2021cited by 43position: middledoi
Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)
Orphanet Journal of Rare Diseases 2021cited by 43position: middledoi
Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry
Frontiers in Neurology 2021cited by 35position: middledoi
TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
Frontiers in Neurology 2021cited by 21position: middledoi
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
JAMA Neurology 2020cited by 256position: middledoi
Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas
Frontiers in Neurology 2020cited by 64position: middledoi
Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
Frontiers in Neurology 2020cited by 49position: middledoi
Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype.
PubMed 2020cited by 36position: middledoi
Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project
Journal of Neurodevelopmental Disorders 2020cited by 35position: middledoi
Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
Frontiers in Neurology 2019cited by 53position: middledoi
Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study
Frontiers in Neurology 2019cited by 34position: middledoi
Epilepsy in tuberous sclerosis complex: Findings from the <scp>TOSCA</scp> Study
Epilepsia Open 2018cited by 236position: middledoi
TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study
Orphanet Journal of Rare Diseases 2018cited by 188position: middledoi
Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial
The Lancet Child & Adolescent Health 2018cited by 116position: middledoi
Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness
Molecular Genetics & Genomic Medicine 2018cited by 113position: middledoi
Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness
Nephrology Dialysis Transplantation 2018cited by 111position: middledoi
Everolimus dosing recommendations for <scp>tuberous sclerosis complex–</scp>associated refractory seizures
Epilepsia 2018cited by 50position: middledoi
TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
Orphanet Journal of Rare Diseases 2017cited by 279position: middledoi
<i>GRIN2B</i> encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects
Journal of Medical Genetics 2017cited by 254position: middledoi
Management Strategies for CLN2 Disease
Pediatric Neurology 2017cited by 118position: middledoi
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
The Lancet 2016cited by 747position: middledoi
Phenotypic insights into <i>ADCY5</i>‐associated disease
Movement Disorders 2016cited by 124position: middledoi
Ten-Year Single-Center Experience of the Ketogenic Diet: Factors Influencing Efficacy, Tolerability, and Compliance
The Journal of Pediatrics 2015cited by 83position: middledoi
Obesity in mice with adipocyte-specific deletion of clock component Arntl
Nature Medicine 2012cited by 457position: middledoi
Prostaglandin D <sub>2</sub> Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia
Science Translational Medicine 2012cited by 299position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David Neal Franz · University of Cape Town4 papers (2016–2021)Zühal Yapıcı · University of Cape Town4 papers (2016–2021)Jacqueline A. French · Epilepsy Foundation4 papers (2016–2021) · 3 papers (2016–2021)Paolo Curatolo · University of Cape Town3 papers (2016–2021)Maurizio Voi · University of Cape Town3 papers (2016–2018)Petrus J. de Vries · University of Cape Town3 papers (2016–2021)Hiroko Ikeda · University of Cape Town3 papers (2016–2021)Rima Nabbout · University of Cape Town3 papers (2016–2021)Dennis Dlugos · Epilepsy Foundation3 papers (2016–2021)Tilman Polster · University of Cape Town3 papers (2016–2021)Rani Sachdev · UNSW Sydney2 papers (2016–2018)Michael Cardamone · The University of Sydney2 papers (2015–2018)Alexandra Johnson · University of Manchester2 papers (2018–2022)Séverine Peyrard · Novartis (Switzerland)2 papers (2016–2021)Garret A. FitzGerald · Dalian Medical University2 papers (2012–2012)Ellen Hurley · UNSW Sydney1 papers (2022–2022)Edwin P. Kirk · UNSW Sydney1 papers (2018–2018)Salam A. Ibrahim · University of Delaware1 papers (2012–2012)Marcel E. Dinger · The University of Sydney1 papers (2018–2018)